CA2134239A1 - Pretargeting methods and compounds - Google Patents

Pretargeting methods and compounds

Info

Publication number
CA2134239A1
CA2134239A1 CA002134239A CA2134239A CA2134239A1 CA 2134239 A1 CA2134239 A1 CA 2134239A1 CA 002134239 A CA002134239 A CA 002134239A CA 2134239 A CA2134239 A CA 2134239A CA 2134239 A1 CA2134239 A1 CA 2134239A1
Authority
CA
Canada
Prior art keywords
compounds
methods
biotin
pretargeting methods
radiohalogenation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002134239A
Other languages
French (fr)
Other versions
CA2134239C (en
Inventor
Donald B. Axworthy
Louis J. Theodore
Linda M. Gustavson
John M. Reno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aletheon Pharmaceuticals Inc
Original Assignee
Donald B. Axworthy
Louis J. Theodore
Linda M. Gustavson
John M. Reno
Neorx Corporation
Aletheon Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/895,588 external-priority patent/US5283342A/en
Application filed by Donald B. Axworthy, Louis J. Theodore, Linda M. Gustavson, John M. Reno, Neorx Corporation, Aletheon Pharmaceuticals, Inc. filed Critical Donald B. Axworthy
Publication of CA2134239A1 publication Critical patent/CA2134239A1/en
Application granted granted Critical
Publication of CA2134239C publication Critical patent/CA2134239C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6887—Antibody-chelate conjugates using chelates for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1268—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules host-guest, closed hollow molecules, inclusion complexes, e.g. with cyclodextrins, clathrates, cavitates, fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Abstract

Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.
CA002134239A 1992-06-09 1993-06-07 Pretargeting methods and compounds Expired - Fee Related CA2134239C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US07/895,588 US5283342A (en) 1992-06-09 1992-06-09 Biotinylated small molecules
US07/895,588 1992-06-09
US99538192A 1992-12-23 1992-12-23
US99538392A 1992-12-23 1992-12-23
US07/995,383 1992-12-23
US07/995,381 1992-12-23
PCT/US1993/005406 WO1993025240A2 (en) 1992-06-09 1993-06-07 Pretargeting methods and compounds

Publications (2)

Publication Number Publication Date
CA2134239A1 true CA2134239A1 (en) 1993-12-23
CA2134239C CA2134239C (en) 2004-11-23

Family

ID=27420561

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002134239A Expired - Fee Related CA2134239C (en) 1992-06-09 1993-06-07 Pretargeting methods and compounds

Country Status (7)

Country Link
US (2) US5608060A (en)
EP (2) EP0646019B9 (en)
JP (1) JPH07507804A (en)
AT (1) ATE210464T1 (en)
CA (1) CA2134239C (en)
DE (1) DE69331319T2 (en)
WO (1) WO1993025240A2 (en)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416738B1 (en) 1973-12-07 2002-07-09 Neorx Corporation Pretargeting methods and compounds
US6075010A (en) * 1992-06-09 2000-06-13 Neorx Corporation Small molecular weight ligand-hexose containing clearing agents
US5556982A (en) * 1985-01-14 1996-09-17 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5525338A (en) * 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US5578287A (en) * 1992-06-09 1996-11-26 Neorx Corporation Three-step pretargeting methods using improved biotin-active agent
US6022966A (en) * 1993-11-22 2000-02-08 Neorx Corporation Pretargeting methods and compounds
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
US6358490B2 (en) 1992-06-09 2002-03-19 Neorx Corporation Three-step pretargeting methods and compounds
IL108388A0 (en) * 1993-01-21 1994-04-12 Harvard College Amplified direction of effector groups to specific target cells in an animal
CA2154667A1 (en) * 1993-02-02 1994-08-18 Linda M. Gustavson Directed biodistribution of small molecules
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
CA2163107C (en) * 1993-05-17 2001-04-17 David Milton Goldenberg Improved detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates
US6120768A (en) * 1993-05-17 2000-09-19 Immunomedics, Inc. Dota-biotin derivatives
CA2165538A1 (en) * 1993-08-17 1995-02-23 Sudhakar Kasina S3n chelating compounds for the radiolabeling of ligands, anti-ligands or other proteins
EP0743956A4 (en) * 1993-12-07 1999-03-24 Neorx Corp Pretargeting methods and compounds
CA2178476A1 (en) * 1993-12-07 1995-06-15 Neorx Corporation Pretargeting methods and compounds
US6015897A (en) * 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
IL112372A (en) * 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
ATE268186T1 (en) * 1994-06-06 2004-06-15 Thejmde Trust BIOTIN COMPOUNDS TO TARGE TUMORS AND SIGNS OF INFECTION
US5716594A (en) * 1994-06-06 1998-02-10 The Jmde Trust Biotin compounds for targetting tumors and sites of infection
JPH0889278A (en) * 1994-09-29 1996-04-09 Ajinomoto Co Inc Modified protein for introducing gene and its production
US6172045B1 (en) * 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
US6908903B1 (en) 1994-12-07 2005-06-21 Aletheon Pharmaceuticals, Inc. Cluster clearing agents
US5955605A (en) * 1995-02-21 1999-09-21 Neorx Corporation Biotinidase resistant biotin-DOTA conjugates
US6155266A (en) * 1995-05-08 2000-12-05 Maxim Pharmaceuticals, Inc. Method for treatment of cancer and infectious disease
EP0837696B1 (en) * 1995-06-07 2010-02-24 Immunomedics, Inc. Improved delivery of diagnostic and therapeutic agents to a target site
US5846537A (en) * 1995-06-07 1998-12-08 University Of Rochester Modified avidin and streptavidin and methods of use thereof
US5739313A (en) * 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
KR100485240B1 (en) * 1996-01-11 2006-10-24 테크니클론 인크. Antibodies with reduced net charge
US20010023288A1 (en) * 1999-07-07 2001-09-20 Wilbur D. Scott Trifunctional reagent for conjugation to a biomolecule
CA2257353A1 (en) * 1996-06-06 1997-12-11 Louis J. Theodore Liver retention clearing agents
WO1998015564A1 (en) * 1996-10-08 1998-04-16 Kreatech Biotechnology B.V. Methods for labeling nucleotides, labeled nucleotides and useful intermediates
CA2283716A1 (en) * 1997-03-14 1998-09-17 Gabriel O. Reznik Multiflavor streptavidin
US6376471B1 (en) * 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
EP1107784A2 (en) * 1998-08-24 2001-06-20 Maxim Pharmaceuticals, Inc. Activation and protection of t-cells (cd4?+ and cd8?+ ) using an h 2? receptor agonist and other t-cell activating agents
IL131266A0 (en) 1999-08-05 2001-01-28 N S T Neurosurvival Technologi Peptides and pharmaceutical compositions comprising same
IL125908A (en) 1998-08-24 2005-05-17 Nst Neurosurvival Technologies Peptides and pharmaceutical compositions comprising same
US6365379B1 (en) * 1998-10-06 2002-04-02 Isis Pharmaceuticals, Inc. Zinc finger peptide cleavage of nucleic acids
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
CA2363067C (en) 1999-01-12 2012-03-20 David J. Grainger Compounds and methods to inhibit or augment an inflammatory response
EP1131099A2 (en) * 1999-01-15 2001-09-12 Light Sciences Corporation Noninvasive vascular therapy
US6602274B1 (en) * 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
JP2002534483A (en) * 1999-01-15 2002-10-15 ライト サイエンシーズ コーポレイション Therapeutic compositions for metabolic bone disorders or bone metastases
US6454789B1 (en) * 1999-01-15 2002-09-24 Light Science Corporation Patient portable device for photodynamic therapy
US6806363B1 (en) * 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
WO2000071171A2 (en) * 1999-05-21 2000-11-30 Wake Forest University Sigma-1 ligands for determining carcinoma proliferative status
CA2376192A1 (en) * 1999-06-07 2000-12-14 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US20030143233A1 (en) * 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
US20030103948A1 (en) * 1999-06-07 2003-06-05 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
AU5871000A (en) * 1999-06-11 2001-01-02 Paul G. Abrams High dose radionuclide complexes for bone marrow suppression
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
US7591995B2 (en) * 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
WO2001028595A1 (en) 1999-10-15 2001-04-26 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
JP2003512338A (en) * 1999-10-15 2003-04-02 メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ Cobalamin conjugates useful as contrast agents and antitumor agents
US7067111B1 (en) * 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
DE19956029A1 (en) * 1999-11-22 2001-05-23 Aventis Pharma Gmbh Active substance carrier system based on coating a substance with enzymatically cleavable side groups, useful for gene therapy especially of cancer and inflammation
EP1267935A2 (en) 2000-01-12 2003-01-02 Light Sciences Corporation Novel treatment for eye disease
NO312708B1 (en) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioactive liposomes for therapy
BRPI0111220B8 (en) * 2000-06-02 2021-07-27 Univ Texas drug conjugates with ethylenedicysteine (ec)
AU2001288829A1 (en) * 2000-09-06 2002-03-22 Ap Pharma, Inc. Degradable polyacetal polymers
EP1334114A2 (en) * 2000-10-25 2003-08-13 Mayo Foundation For Medical Education And Research Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
JP2004536034A (en) * 2001-01-08 2004-12-02 ネオルクス コーポレイション Therapeutic and diagnostic compounds, compositions and methods
ITRM20010079A1 (en) * 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti ADMINODERIVATES OF BIOTIN AND THEM CONJUGATED WITH MACROCYCLIC CHELANTS.
US7635680B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
EP1379266B1 (en) * 2001-02-21 2007-04-18 SurroMed, Inc. Modified annexin proteins and prevention and treatment of thrombosis
US20090291086A1 (en) * 2001-02-21 2009-11-26 Alavita Pharmaceuticals, Inc. Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7645739B2 (en) * 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
AU2002322275A1 (en) * 2001-06-20 2003-01-08 Mayo Foundation For Medical Education And Research Adenosyl-cobalamin fortified compositions
US20060074034A1 (en) * 2001-09-17 2006-04-06 Collins Douglas A Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
CA2461705A1 (en) * 2001-09-28 2003-04-03 Mayo Foundation For Medical Education And Research Coadministration of transport protein with conjugated cobalamin to deliver agents
WO2003061696A2 (en) * 2002-01-23 2003-07-31 Light Sciences Corporation Systems and methods for photodynamic therapy
US6982154B2 (en) * 2002-02-21 2006-01-03 Surromed, Inc. Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease
ITRM20020128A1 (en) * 2002-03-08 2003-09-08 Sigma Tau Ind Farmaceuti DIMERI OF AVIDINA EFFECTIVE IN INCREASING THE CONCENTRATION OF RADIOACTIVE BIOTIN IN IMMUNOTHERAPY WITH "PRETARGETING".
WO2003077865A2 (en) * 2002-03-15 2003-09-25 Baxter International Inc. Methods and compositions for directing cells to target organs
KR100440725B1 (en) * 2002-06-20 2004-07-15 주식회사 그린진 바이오텍 A Method for Increasing an Abiotic-Resistance in Monocot Plants
KR20050062605A (en) * 2002-10-10 2005-06-23 디파트먼트 오브 베테랑스 어페어스 오피스 오브 더 제네럴 카운셀 (024) Detection, localization and staging of tumors using labeled activated lymphocytes directed to a tumor specific epitope
US7534431B2 (en) * 2003-01-31 2009-05-19 Immunomedics, Inc. Methods and compositions for administering therapeutic and diagnostic agents
WO2005051429A2 (en) * 2003-11-19 2005-06-09 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeted conjugates with a modified saccharide linker
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
WO2005114192A1 (en) * 2004-05-13 2005-12-01 Centre National De La Recherche Scientifique A device for binding a target entity to a bait entity and detection methods using the same
US20050271585A1 (en) * 2004-06-07 2005-12-08 General Electric Company Extended conjugated polymers
US20060057062A1 (en) * 2004-09-10 2006-03-16 Trotter Dinko G Compositions and methods useful in pretargeted imaging
EP1799273A2 (en) * 2004-10-07 2007-06-27 Koninklijke Philips Electronics N.V. Use of the staudinger ligation in imaging and therapy end kits for imaging and therapy
BRPI0610419A2 (en) * 2005-05-17 2012-10-23 Cargill Inc granular lecithin, lysolecithin, process for producing granular lecithin, granular composition, process for producing a granular lecithin composition, product, and, processes for producing granular lysolecithin and for producing a granular lysolecithin composition
TWI381852B (en) * 2005-09-27 2013-01-11 Sigma Tau Ind Farmaceuti Biotin diaminoderivatives and their conjugates with macrocyclic chelating agents
US8758723B2 (en) * 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
EP2399993B1 (en) 2009-02-20 2017-09-20 The University of Tokyo Hypo-immunogenic streptavidin and use thereof
FI20090100A0 (en) 2009-03-16 2009-03-16 Wallac Oy Biotinidaasimääritys
GB0922369D0 (en) 2009-12-22 2010-02-03 Hammersmith Imanet Ltd Labelled biotin conjugates
MX350974B (en) 2010-11-18 2017-09-27 Univ Yale Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus.
GB201205360D0 (en) 2012-03-27 2012-05-09 Univ Edinburgh Biotinidase resistant biotinyl compounds
JP6178586B2 (en) * 2013-02-20 2017-08-09 サヴィッド・セラピューティックス株式会社 Biotin variants, streptavidin variants and their use
EP3068443B1 (en) 2013-11-12 2019-04-10 Centre for Probe Development and Commercialization Residualizing linkers and uses thereof
US11286285B2 (en) 2014-02-18 2022-03-29 Savid Therapeutics Inc. Modified biotin, streptavidin mutant, and usage of them
EP3316871A4 (en) 2015-06-30 2019-02-20 The Trustees of Columbia University in the City of New York Talc-bound compositions and uses thereof
EP3546470A4 (en) 2016-11-25 2020-08-05 Savid Therapeutics Inc. Clearing agent
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
EP3619191A4 (en) 2017-05-05 2020-12-16 Fusion Pharmaceuticals Inc. Pharmacokinetic enhancements of bifunctional chelates and uses thereof
BR112019023249A8 (en) 2017-05-05 2021-02-23 Centre For Probe Dev And Commercialization igf-1r monoclonal antibodies and their uses
EP3805235A4 (en) 2018-05-30 2022-03-16 The University of Tokyo Halogenated biotin-modified dimer and use thereof
WO2019241609A1 (en) * 2018-06-15 2019-12-19 Trustees Of Boston University Polypeptide compositions and methods for site-specific targeting of therapeutic agents
US20220016245A1 (en) 2018-08-08 2022-01-20 The University Of Tokyo Conjugate of biotin-modified dimer and phthalocyanine dye
MX2022009419A (en) 2020-01-31 2022-08-25 Avilar Therapeutics Inc Asgpr-binding compounds for the degradation of extracellular proteins.
WO2021210573A1 (en) 2020-04-14 2021-10-21 国立大学法人 東京大学 Biotin-modified dimer and use thereof
WO2021215534A1 (en) 2020-04-24 2021-10-28 国立大学法人 東京大学 Duocarmycin derivative and use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
NZ211453A (en) * 1984-03-22 1989-01-06 Biotechnology Research Enterpr Aryl azides, their preparation and use in the detection, localisation and isolation of polynucleotides
US4639365A (en) * 1984-10-18 1987-01-27 The Board Of Regents, The University Of Texas System Gadolinium chelates as NMR contrast agents
US4678667A (en) * 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
KR950001704B1 (en) * 1986-07-03 1995-02-28 디 엎죤 캄파니 Process for the preparation of antibiotics 10381b
US5246692A (en) * 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
FR2604092B1 (en) * 1986-09-19 1990-04-13 Immunotech Sa IMMUNOREACTIVES FOR TARGETING ANIMAL CELLS FOR VISUALIZATION OR DESTRUCTION IN VIVO
DE3713842A1 (en) * 1987-04-22 1988-11-17 Schering Ag SUBSTITUTED CYCLIC COMPLEX MAKERS, COMPLEX AND COMPLEX SALTS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THEM
DE3722647A1 (en) * 1987-07-09 1989-01-19 Gerhard Ohlenschlaeger GALENIC USE OF A TRIPEPTID AS A MEDICINAL PRODUCT
DK47389A (en) * 1988-02-03 1989-08-04 Hybritech Inc PHARMACOKINETICALLY MODIFIED HAPTEN DERIVATIVES FOR RADIO LABELING ANTIBODIES OR USED AS RADIOTHERAPEUTIC AGENTS
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US4923985A (en) * 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
US4895955A (en) * 1988-05-27 1990-01-23 Lifecodes Corporation Non-radioactive carbodiimide precursor to nucleic acid probes
WO1990000565A1 (en) * 1988-07-05 1990-01-25 Amgen Inc. Interleukin ii analogs
US5364613A (en) * 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
SE465155B (en) * 1989-12-19 1991-08-05 Exploaterings Ab Tbf METAL CHELET FORMING HYDROPHIL POLYMER FOR ADSORPTION ETC AND A SAT FOR PREPARATION OF THE POLYMER
CA2070647C (en) * 1989-12-27 2001-04-10 Christiaan Reutelingsperger Use of an anticoagulant as a diagnostic agent
JP2776953B2 (en) * 1990-04-10 1998-07-16 日本メジフィジックス株式会社 Multifunctional metal chelate compounds and their uses
DE4035760A1 (en) * 1990-11-08 1992-05-14 Schering Ag MONO-N-SUBSTITUTED 1,4,7,10-TETRAAZACYCLODODECAN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THEM
IT1245748B (en) * 1990-12-21 1994-10-14 Mini Ricerca Scient Tecnolog PREPARATION INCLUDING BIOTINYLATE MONOCLONAL ANTIBODIES, AVIDIN AND BIOTIN, FOR DIAGNOSIS OF CANCER DISEASES AND ITS USE
US5326778A (en) * 1992-03-03 1994-07-05 Research Corporation Technologies, Inc. Conjugates of biotin and deferoxamine for radioimmunoimaging and radioimmunotherapy
CA2154667A1 (en) * 1993-02-02 1994-08-18 Linda M. Gustavson Directed biodistribution of small molecules

Also Published As

Publication number Publication date
JPH07507804A (en) 1995-08-31
CA2134239C (en) 2004-11-23
EP0646019B9 (en) 2002-12-18
WO1993025240A3 (en) 1994-02-17
EP0646019A1 (en) 1995-04-05
DE69331319T2 (en) 2002-08-08
DE69331319D1 (en) 2002-01-24
US5608060A (en) 1997-03-04
EP0646019B1 (en) 2001-12-12
US5630996A (en) 1997-05-20
ATE210464T1 (en) 2001-12-15
EP1138334A2 (en) 2001-10-04
WO1993025240A2 (en) 1993-12-23
EP1138334A3 (en) 2002-04-03

Similar Documents

Publication Publication Date Title
CA2134239A1 (en) Pretargeting methods and compounds
AU6284296A (en) Improvements in or relating to organic compositions
BG102425A (en) (methylsulphonyl)phenyl-2-(5h)-furanons as cyclooxygenase-2-inhibitors
AU603525B2 (en) Tetrazole intermediates to antihypertensive compounds
NZ514330A (en) Zinc containing dentifrice compositions
AU2432795A (en) Composition for ultrasonically quantitating myocardial perfusion
IL115790A0 (en) Pharmaceutical compositions containing boronic ester and acid compounds and methods for the preparation thereof
CA2195856A1 (en) Substituted o6-benzylguanines and use thereof
CA2172513A1 (en) Aminocyclohexylesters and uses thereof
AU4075299A (en) N,n'-azobis-nitroazoles and analogs thereof as igniter compounds for use in energetic compositions
ES2181501T3 (en) COSMETIC COMPOSITION.
HUP9900800A3 (en) Improvements in or relating to organic compositions
CA2161641A1 (en) Stable, ingestable and absorbable nadh and nadph therapeutic compositions
CA2317793A1 (en) Laxative composition
EP0630260A4 (en) Polysaccharide-protein conjugates.
IT1235327B (en) SKI BOOT STRUCTURE.
GB2283493B (en) Improvements in or relating to photopolymerizable compositions
GB9521101D0 (en) Improvements in or relating to organic compositions
AU9170998A (en) Compositions for cultivating soil with reduced fertility
EP0381504A3 (en) Improvements in and relating to guanidine derivatives
UA42722C2 (en) Sulphides, sulphoxides and sulphones or the pharmaceutically acceptable salts thereof and pharmaceutical composition containing them
GR3031118T3 (en) Novel seco-D steroids active in the cardiovascular system and pharmaceutical compositions containing same
IT1216102B (en) MECHANISM TO ADJUST THE APPROACH OF A TRAILER TO THE TRAILING VEHICLE, BOTH AS A RESULT OF CHANGES OF DIRECTION AND OF SLOPE CHANGES.
GB9502318D0 (en) Improvement in or relating to organic compositions
ZA905020B (en) Compositions useful as contraceptives in males

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed